Literature DB >> 2328213

How frequent is spontaneous remission of neuroblastomas? Implications for screening.

N L Carlsen1.   

Abstract

The 'true' incidence of spontaneous regression of neuroblastomas is uncertain. However, the frequency of spontaneous regression is important when the benefits of screening procedures are considered. In the population-based Danish neuroblastoma survey 1943-80, spontaneous regression was documented in less than 2% of cases. However, the 'true' incidence may be higher. The epidemiological findings of increased incidence and survival rates with an unchanged mortality rate may suggest the inclusion of borderline lesions among 'truly' malignant neuroblastomas in recent decades in Denmark. However, it is more likely to be a result of improved diagnosis, changes in the social composition of the population and possibly unidentified environmental agents. However, if some premalignant lesions in fact had been included, they are most likely to be stages I-II tumours of infancy. In this study we describe cases of spontaneous regression of neuroblastoma from the Danish population-based survey 1943-80.

Entities:  

Mesh:

Year:  1990        PMID: 2328213      PMCID: PMC1971306          DOI: 10.1038/bjc.1990.97

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  42 in total

1.  Why age has independent prognostic significance in neuroblastomas. Evidence for intra-uterine development, and implications for the treatment of the disease.

Authors:  N L Carlsen
Journal:  Anticancer Res       Date:  1988 Mar-Apr       Impact factor: 2.480

2.  Screening for neuroblastoma.

Authors:  A M Mauer
Journal:  J Pediatr       Date:  1988-04       Impact factor: 4.406

3.  Chromosomes and screening for neuroblastoma.

Authors:  Y Kaneko; N Maseki; M Sakurai; I Okabe; T Takeda; M Sakurai; N Kanda
Journal:  Lancet       Date:  1988-01-23       Impact factor: 79.321

4.  Incidental neuroblastoma.

Authors:  T Sawada; H Kawakatu; Y Horii; T Sugimoto
Journal:  Lancet       Date:  1988-02-13       Impact factor: 79.321

5.  Screening for neuroblastoma.

Authors:  M G Norman; J E Dimmick; G P Taylor; M Teasdale
Journal:  Lancet       Date:  1987-09-05       Impact factor: 79.321

6.  "Incidental" neuroblastoma.

Authors:  A M Kosloske; N Bhattacharyya; M H Duncan
Journal:  Lancet       Date:  1987-09-05       Impact factor: 79.321

7.  Chromosome findings and prognosis in 15 patients with neuroblastoma found by VMA mass screening.

Authors:  Y Hayashi; T Inaba; R Hanada; K Yamamoto
Journal:  J Pediatr       Date:  1988-04       Impact factor: 4.406

8.  Feasibility of chemical screening of urine for neuroblastoma case finding in infancy in Quebec.

Authors:  C R Scriver; D Gregory; M Bernstein; C L Clow; T Weisdorf; G E Dougherty; C Auray-Blais; R Giguère; B Lemieux; C Laberge
Journal:  CMAJ       Date:  1987-05-01       Impact factor: 8.262

9.  Signs, symptoms, metastatic spread and metabolic behavior of neuroblastomas treated in Denmark during the period 1943-1980.

Authors:  N L Carlsen; H Schroeder; I J Christensen; P V Bro; U Hesselbjerg; K B Jensen; O H Nielsen
Journal:  Anticancer Res       Date:  1987 May-Jun       Impact factor: 2.480

10.  Neuroblastoma: the case for screening infants in North America.

Authors:  W G Woods; M Tuchman
Journal:  Pediatrics       Date:  1987-06       Impact factor: 7.124

View more
  12 in total

1.  Comparison of clinico-radiological features between congenital cystic neuroblastoma and neonatal adrenal hemorrhagic pseudocyst.

Authors:  Hong Eo; Ji Hye Kim; Kyung Mi Jang; So-Young Yoo; Gye-Yeon Lim; Myung-Joon Kim; Ok-Hwa Kim
Journal:  Korean J Radiol       Date:  2011-01-03       Impact factor: 3.500

Review 2.  Recent advances in neuroblastoma.

Authors:  John M Maris
Journal:  N Engl J Med       Date:  2010-06-10       Impact factor: 91.245

3.  Spontaneous regression of an invasive thymoma.

Authors:  Yojiro Yutaka; Mitsugu Omasa; Kei Shikuma; Masato Okuda; Toshihiko Taki
Journal:  Gen Thorac Cardiovasc Surg       Date:  2009-05-15

4.  Chromosome 6p22 locus associated with clinically aggressive neuroblastoma.

Authors:  John M Maris; Yael P Mosse; Jonathan P Bradfield; Cuiping Hou; Stefano Monni; Richard H Scott; Shahab Asgharzadeh; Edward F Attiyeh; Sharon J Diskin; Marci Laudenslager; Cynthia Winter; Kristina A Cole; Joseph T Glessner; Cecilia Kim; Edward C Frackelton; Tracy Casalunovo; Andrew W Eckert; Mario Capasso; Eric F Rappaport; Carmel McConville; Wendy B London; Robert C Seeger; Nazneen Rahman; Marcella Devoto; Struan F A Grant; Hongzhe Li; Hakon Hakonarson
Journal:  N Engl J Med       Date:  2008-05-07       Impact factor: 91.245

Review 5.  Targeting ALK in neuroblastoma--preclinical and clinical advancements.

Authors:  Erica L Carpenter; Yael P Mossé
Journal:  Nat Rev Clin Oncol       Date:  2012-05-15       Impact factor: 66.675

Review 6.  Development of treatment strategies for advanced neuroblastoma.

Authors:  Junichi Hara
Journal:  Int J Clin Oncol       Date:  2012-05-16       Impact factor: 3.402

7.  miRNA-34a-5p regulates progression of neuroblastoma via modulating the Wnt/β-catenin signaling pathway by targeting SOX4.

Authors:  Yue Wang; Enqing Guan; Dehua Li; Lirong Sun
Journal:  Medicine (Baltimore)       Date:  2021-05-21       Impact factor: 1.817

8.  Late Recurrence in Breast Cancer: To Run after the Oxen or to Try to Close the Barn?

Authors:  Romano Demicheli; Elia Biganzoli
Journal:  Cancers (Basel)       Date:  2021-04-22       Impact factor: 6.639

Review 9.  Is neuroblastoma screening evaluation needed and feasible?

Authors:  J Estève; L Parker; P Roy; F Herrmann; S Duffy; D Frappaz; C Lasset; C Hill; H Sancho-Garnier; J Michaelis
Journal:  Br J Cancer       Date:  1995-06       Impact factor: 7.640

10.  Unchanged incidence and increased survival in children with neuroblastoma in Denmark 1981-2000: a population-based study.

Authors:  H Schroeder; J Wacher; H Larsson; S Rosthoej; C Rechnitzer; B L Petersen; B L Pedersen; N L T Carlsen
Journal:  Br J Cancer       Date:  2009-02-17       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.